Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRace Oncology Limited

Race Oncology Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-08-11T13:01:24.199151Z
Market Cap
135.61M

Momentum Score

…

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.45
Low
1.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
3.13M
Revenue Per Share
0.02
Gross Profit TTM
1.11M
Debt / Equity
-
ROE
-32.22%
Net Debt
-
ROCE
-41.10%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -9.92M -11.20M -6.34M -3.85M -3.66M
Net income -9.92M -11.20M -6.34M -3.85M -3.66M
Selling general administrative 1.77M 3.96M 2.91M 1.68M 2.30M
Reconciled depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Ebit -10.48M -11.20M -6.36M -3.93M -3.67M
Ebitda -13.37M -11.53M -6.50M -3.83M -3.62M
Operating income -13.65M -11.81M -6.78M -4.11M -3.91M
Other operating expenses 0.66M 0.48M 0.31M 0.14M 0.14M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.59M 0.05M 0.02M 0.01M 0.02M
Net interest income 0.59M 0.05M 0.02M 0.01M 0.02M
Total other income expense net 3.13M 0.56M 0.42M 0.26M 0.23M
Net income from continuing ops -9.92M -11.20M -6.34M -3.85M -3.66M
Net income applicable to common shares -9.92M -11.20M -6.34M -3.85M -3.66M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 26.64M 37.52M 14.25M 5.93M 5.24M
Intangible assets 3.09M 3.37M 3.66M 3.94M 4.22M
Other current assets - - - 0.18M 0.03M
Total liab 1.15M 1.42M 0.52M 0.24M 0.19M
Total stockholder equity 25.49M 36.11M 13.72M 5.69M 5.05M
Other current liab - - 0.00M - 0.03M
Common stock 61.71M 62.02M 31.50M 19.66M 15.42M
Capital stock 61.71M 62.02M 31.50M 19.66M 15.42M
Retained earnings -43.60M -33.68M -22.47M -15.77M -13.43M
Cash 21.52M 33.54M 9.32M 1.73M 0.99M
Total current liabilities 1.15M 1.42M 0.52M 0.24M 0.19M
Other stockholder equity 7.38M 7.77M 4.69M 1.80M 3.05M
Total current assets 23.54M 34.15M 10.59M 2.00M 1.02M
Net tangible assets 22.39M 32.73M 10.07M 1.75M 0.83M
Net receivables 1.70M 0.06M 0.13M 0.05M 0.00M
Accounts payable 0.64M 0.83M 0.31M 0.13M 0.10M
Non current assets total 3.09M 3.37M 3.66M 3.94M 4.22M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Change to liabilities -0.27M 0.89M 0.28M 0.05M -0.12M
Total cash from financing activities -1.28M 30.51M 12.28M 3.21M -0.03M
Change to operating activities 0.23M 0.59M -1.11M 0.00M -0.00M
Net income -9.92M -11.20M -6.34M -3.85M -3.66M
Change in cash -12.02M 24.22M 7.59M 0.74M -2.72M
Begin period cash flow 33.54M 9.32M 1.73M 0.99M 3.71M
End period cash flow 21.52M 33.54M 9.32M 1.73M 0.99M
Total cash from operating activities -10.65M -6.26M -4.70M -2.46M -2.67M
Issuance of capital stock -1.28M 30.98M 12.79M 3.34M -
Depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Change to account receivables -1.64M 0.07M -0.08M -0.05M -0.00M
Sale purchase of stock - -0.46M -0.51M -0.14M -0.03M
Other cashflows from financing activities -1.28M -0.46M -0.51M -0.14M -0.03M
Change to netincome 0.67M 3.11M 2.27M 1.10M 0.83M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Free cash flow -10.65M -6.26M -4.70M -2.46M -2.67M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Race Oncology Limited

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000

61 2 8051 3043

https://www.raceoncology.com

Name Title Year Born
Mr. Phillip R. Lynch CEO, MD & Director NA
Dr. Daniel Tillett Chief Scientific Officer & Exec. Director NA
Ms. Christina Manfre Chief Financial Officer NA
Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP Interim Chief Medical Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…